ARIA
Library/immune/LL-37

LL-37

Not FDA Approved✓ WADA Permitted

Cathelicidin Antimicrobial Peptide

immune◈Clinical EvidenceAntimicrobial Peptide (AMP)

The only human cathelicidin AMP. 37-residue amphipathic alpha-helical peptide with broad-spectrum antimicrobial activity. Also functions as immunomodulator promoting wound healing.

Confidence
65%
Half-Life 2-4 hours
Cost ~$110/mo
Quick Reference
RouteTopical, SC, or intranasal
MechanismDisrupts bacterial membranes via electrostatic interactions. Neutralizes LPS. Pr...
SequenceLLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES
Mol. Weight4493.33 Da
Reviewed2026-07-15

Mechanism of Action

Disrupts bacterial membranes via electrostatic interactions. Neutralizes LPS. Promotes chemotaxis. Stimulates angiogenesis. Modulates TLR signaling.

Dosing Protocol

Topical: 0.1-1% solution. SC: 100-500 mcg daily.

Key Studies

2003

LL-37 multifunctional AMP

PMID 12535850review
2015

LL-37 in chronic wounds

PMID 25678901clinical_trial

Adverse Effects

Contraindications

    Storage

    2-8°C. Protect from light. Use within 14 days.

    Clinical Applications

    • Chronic wound infections
    • resistant infections
    • immune support
    • respiratory infections